Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer

Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer

Background: Circulating tumor DNA (ctDNA) is a novel biomarker to predict recurrence in colorectal cancer (CRC). However, clinical validation data in underrepresented patient populations like Southeast Asians are lacking. Materials and methods: In our prospective clinical trial, 92 patients with sta...

Full description

Saved in:
Bibliographic Details
Main Authors: H.T. Nguyen, V.-A. Nguyen Hoang, T.V. Nguyen, N.A.L. Trinh, T.H. Pham, D.N. Le, H.H. Ho, T.D. Nguyen, H.D. Nguyen, T.S.L. Thi, N. Nguyen, D.H. Tran, M.T. Le, T.C. Dinh, T.S. Nguyen, K.C.N. The, H. Mai, M.T. Chu, D.H. Pham, N.H.T. Phuc, D.N. Vinh, D.-N. Nguyen, X.-V. Nguyen, D.S. Nguyen, T.T.D. Thi, H. Giang, H.-N. Nguyen, L.N. Tu
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
minimal residual disease (MRD)
disease-free survival (DFS)
circulating tumor DNA
colorectal cancer
recurrence
prognosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000547
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items